“The end game is literature-based drug discovery,” Nadler said, referencing the field of data mining scientific literature for insights. “The economic value of that as a company is going to dwarf by orders of magnitude whatever we could have charged hospitals or advertisers.”

Alexander Tarashansky, the creator of Claude Science, an Anthropic platform that supports research scientists, has also joined the company to support its clinical work.

The company needs to see off competition from frontier AI companies such as OpenAI, which has also made a play for the space with ChatGPT for healthcare.…